Advancing Mesenchymal Stromal Cell Therapies for High Unmet Need Autoimmune Indications

• Demonstrating clinical value in steroid and JAK inhibitor refractory patients to position MSCs as a late-line option
• Showcasing validated potency assays to link cell quality with improved clinical outcomes
• Exploring allogeneic off-the-shelf MSC approaches to deliver broad immunosuppression with strong safety profiles

Speakers:

Teresa Montagut

Head of Clinical Development & Medical Affairs

Mesoblast Ltd.